Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Solid Tumors: early-phase trial registry
43 of 127 indexed Solid Tumors trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #93 of 28,707 conditions by registered trial count.
127 US clinical trials · 43 currently recruiting · #93 of 28,707 conditions by registered trial count
Solid Tumors: 127 US clinical trials tracked, 43 recruiting.
Solid Tumors is the subject of 127 registered US clinical trials on ClinicalTrials.gov, 43 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 117 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 8 of these trials.
Enrollment posture brief
Registry condition solid-tumors
OPEN 43 | RECR 34% | LATE 4 | EARLY 117 | RANK #93 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Refractory Multiple Myeloma (34% recruiting · 68 trials)
Solid Tumors lists 43 open slots (34% of 127 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Solid Tumors on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Solid Tumors is recruiting below its size-band peers.
43 of 127 indexed trials (33.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Solid Tumors trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 8 of 127 trials (6.3%). 77 distinct sponsors appear on at least one study for this condition label.
-
Typical Solid Tumors enrolment sits around 70 participants.
Median target enrolment is 70 among the 126 trials that report a genuine target (sentinel values excluded). 72 of those (57.1%) plan for fewer than 100 participants.
-
Solid Tumors research is mostly interventional.
122 interventional and 5 observational studies make up this index (96.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
127 total, page 3 of 3
Phase 1 Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors
Amgen
NCT01129349
Phase II Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Tumors of the Lung
New Mexico Cancer Research Alliance
NCT00832780
Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors
Curis
NCT02307240
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
Polaris Group
NCT01497925
A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors
OncoMed Pharmaceuticals
NCT01277146
Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors
Syndax Pharmaceuticals
NCT05731947
A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin
AstraZeneca
NCT04118842
Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants
Duke University
NCT00606437
Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors
Traws Pharma
NCT01125891
Safety Study of ASONEP (Sonepcizumab/LT1009) to Treat Advanced Solid Tumors
Lpath
NCT00661414
Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma
Arno Therapeutics
NCT00978523
A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC
OncoMed Pharmaceuticals
NCT01957007
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
Santa Maria Biotherapeutics
NCT02262455
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas
National Cancer Institute (NCI)
NCT00553189
ABI-009 Trial in Patients With Advanced Non-hematologic Malignancies
Celgene
NCT00635284
Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT01294670
Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors
Daiichi Sankyo
NCT01149720
Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors
University of California, Davis
NCT01336842
Phase I Study of Capecitabine in Combination With Cisplatin and Irinotecan
University of New Mexi
NCT00249977
Patient-Reported Outcomes Version of Common Terminology Criteria (CTCPRO) Cognitive Debriefing
M.D. Anderson Cancer Center
NCT00909207
Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287)
Daiichi Sankyo
NCT01957280
Study of Vinblastine and Sirolimus in Children With Recurrent/Refractory Solid Tumours Including CNS Tumours
The Hospital for Sick Children
NCT01135563
A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer or Other Select Solid Cancers
Bayer
NCT06345001
Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)
National Cancer Institute (NCI)
NCT04574583
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).
Abbott
NCT01021358
Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors
National Cancer Institute (NCI)
NCT01259479
Topotecan, Ifosfamide and Carboplatin in Children and Young Adults With Solid Tumors
M.D. Anderson Cancer Center
NCT00502892
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 102 |
| Phase 2 | 15 |
| Phase 3 | 3 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Solid Tumors records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Solid Tumors trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Solid Tumors page
127 registered trials, 43 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 43 Solid Tumors trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Solid Tumors trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Solid Tumors condition card totals 127 registered trials; most-linked intervention Gemcitabine; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.